Gain insight into how different drugs impact patient outcomes in order to support decision-making during the drug development lifecycle.
On average, new drugs take at least 10 years to reach patients after clinical development begins (PhRMA)
Progress in behavioral health has long been hindered by a lack of standardized measurements, which makes comparison difficult.
Typically, a randomized controlled trial would have to be conducted to assess comparative effectiveness and determine which drug resulted in better outcomes. This process can be time-consuming and costly.
The use of real-world data introduces many opportunities to accelerate and support the drug development process. NeuroBlu solves for traditional challenges in the behavioral health field by providing a variety of broad standardized measures to facilitate comparative effectiveness research, such as the Clinical Global Impressions-Severity (CGI-S) scale, a psychometric scale used to measure illness severity.
In addition, the NeuroBlu Database provides item-level data for scales specific to certain disorders, such as the Abnormal Involuntary Movement (AIMS) scale for schizophrenia or the Quick Inventory of Depressive Symptomology (QIDS) for major depressive disorder.; these scales can be used to identify the presence of certain symptoms, adding valuable context to your research.
Why does this matter?
Findings from comparative effectiveness studies can be used to guide providers' prescribing decisions and improve patient outcomes.
NeuroBlu enables segmentation of patient cohorts into specific sub-cohorts, allowing for comparisons at a more granular level (for example: analyzing how patients with major depressive disorder and anhedonia respond to treatments compared to those without anhedonia). This can provide important information for the development of more targeted treatments for these populations, as well as support accelerated treatment development timelines.